treatment | Charcot–Marie–Tooth Association

CMT2A in the Lab: A Closer Look at How Treatments Are Tested

What if you could watch CMT2A unfold inside a neuron? CMTA’s new partnership just made it possible, and the early findings are changing the game.

How the CMT2C Community Is Driving the Path to Treatment

CMTA Patients as Partners in Research and ActioBiosciences

How is the CMT2C community helping move research forward? A CMTA-hosted focus group on how patient voices are shaping the path to a treatment.

CMTA Invests $281,339 to Advance Treatments for CMT1A

CMTA-STAR funded CMT1A research study led by Yannick Poitelon, PhD, targeting PMP22 and Schwann cells

The newly funded study will test whether molecules originally in development as cancer therapeutics can also be used to lower PMP22 and improve nerve health in a model of CMT1A.

FDA Meeting Could Pave the Way for First CMT Treatment

Major FDA Step for CMT and a Free CMT-SORD Test

Applied Therapeutics secures FDA meeting this fall on its plan to submit govorestat for CMT-SORD. And what’s this about a free SORD test?

Particles on a Mission: Can Nanoparticles Solve One of CMT’s Largest Hurdles?

Can nanoparticles solve one of CMT’s largest hurdles? A team in Cyprus is testing nanoparticle “mail carriers” designed to deliver genetic therapies directly into Schwann cells.

What Can Long-Read Sequencing Reveal About CMT?

What happened when CMTA-supported scientists at University College London applied long-read sequencing to CMT cases that had no genetic confirmation for years?